Transfusion-related acute lung injury (TRALI)

Overview

TRALI is a non-cardiogenic acute lung injury occurring within 6 hours of blood transfusion - one of the leading causes of transfusion-related mortality in the UK. Distinguishing it from TACO is the key clinical and exam challenge.

Pathophysiology

Donor plasma antibodies (anti-HLA class I/II or anti-HNA) react with recipient leucocytes - massive neutrophil activation in pulmonary capillaries
Increased pulmonary capillary permeability → protein-rich alveolar flooding (non-cardiogenic; left atrial pressure is normal)
'Two-hit' model: first hit = pre-existing inflammation (sepsis, surgery, haematological malignancy) primes neutrophils; second hit = transfusion activates them
Most commonly associated with plasma-rich products - FFP and apheresis platelets carry the highest antibody load

Presentation

Onset within 6 hours of transfusion (usually during or shortly after)
Acute breathlessness, non-productive cough, hypoxia (SpO2 drop), tachypnoea, tachycardia
Hypotension - key distinguishing feature from TACO
Fever and rigors - due to inflammatory response
No peripheral oedema, no raised JVP, no hypertension
🎯
TRALI causes hypotension; TACO causes hypertension. Both cause bilateral CXR infiltrates - cardiovascular findings and fluid balance are what separate them.

Investigations

CXR - bilateral pulmonary infiltrates; normal heart size (helps differentiate from TACO)
ABG - confirms hypoxaemia; PaO2:FiO2 <300 mmHg
BNP/NT-proBNP - normal or minimally elevated in TRALI; significantly elevated in TACO - key discriminatory test
FBC - may show transient leucopenia (neutrophil margination in lungs)
Anti-leucocyte antibody testing (HLA class I/II and HNA) - donor and recipient samples; retrospective confirmation
Echocardiography - normal LV function and filling pressures in TRALI; useful when BNP equivocal

Diagnostic criteria

Acute onset of new/worsening respiratory symptoms
Bilateral pulmonary infiltrates on CXR
Hypoxaemia - SpO2 <90% on room air, or PaO2:FiO2 ratio <300 mmHg
No evidence of pre-existing acute lung injury before transfusion
No evidence of circulatory overload (TACO) as the primary cause
Onset within 6 hours of completing blood component transfusion

Management

🥇 First-line

stop the transfusion immediately - keep IV line open with normal saline
high-flow supplemental oxygen via non-rebreather mask; titrate to SpO2 >94%

🥈 Second-line

non-invasive ventilation (CPAP or BiPAP) if hypoxaemia not corrected with high-flow oxygen

🥉 Third-line

invasive mechanical ventilation using lung-protective strategy (low tidal volume, as in ARDS)
Send implicated blood unit and post-transfusion patient sample to blood bank for anti-leucocyte antibody testing
Report via SHOT and to MHRA (Yellow Card scheme) as a serious adverse reaction
⚠️
Diuretics are contraindicated in TRALI - pulmonary oedema is driven by capillary leak, not fluid overload. Diuresis will not resolve alveolar flooding and may precipitate cardiovascular collapse. This is the opposite of TACO management.

Prevention

Male-only plasma donation (UK NHSBT policy) - multiparous women develop HLA antibodies through pregnancy; male donors have very low HLA antibody prevalence
Leucodepletion of all blood components - standard UK practice since 1999
HLA antibody screening of female donors who have been pregnant - deferred from plasma donation if antibodies detected

Prognosis

Most patients improve with supportive care within 48-96 hours; generally better prognosis than ARDS from other causes
Implicated donor must be deferred pending investigation; permanently deferred if antibodies confirmed reactive against recipient antigens

TRALI vs TACO

TRALI vs TACO - key differentiators
FeatureTRALITACO
MechanismNon-cardiogenic (capillary leak)Cardiogenic (fluid overload)
Blood pressureHypotensionHypertension
JVP / peripheral oedemaAbsentRaised JVP, oedema
BNP/NT-proBNPNormal / minimally elevatedSignificantly elevated
CXRBilateral infiltrates, normal heart sizeBilateral infiltrates, cardiomegaly
Fluid balanceNot positivePositive
DiureticsContraindicated - worsens hypotensionFirst-line treatment